[go: up one dir, main page]

MX2009009589A - Gen receptor de celulas t especificas de antigeno cancerigeno, peptido codificado por el gen, y uso de los mismos. - Google Patents

Gen receptor de celulas t especificas de antigeno cancerigeno, peptido codificado por el gen, y uso de los mismos.

Info

Publication number
MX2009009589A
MX2009009589A MX2009009589A MX2009009589A MX2009009589A MX 2009009589 A MX2009009589 A MX 2009009589A MX 2009009589 A MX2009009589 A MX 2009009589A MX 2009009589 A MX2009009589 A MX 2009009589A MX 2009009589 A MX2009009589 A MX 2009009589A
Authority
MX
Mexico
Prior art keywords
gene
cell receptor
specific
cancer antigen
peptide encoded
Prior art date
Application number
MX2009009589A
Other languages
English (en)
Inventor
Haruo Sugiyama
Original Assignee
Int Inst Cancer Immunology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Int Inst Cancer Immunology Inc filed Critical Int Inst Cancer Immunology Inc
Publication of MX2009009589A publication Critical patent/MX2009009589A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0635—B lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • G01N33/5759—
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)

Abstract

Se describen: una secuencia nucleotídica y una secuencia de aminoácidos para la región CDR3 de gen receptor de células T (TCR) de células T citotóxicas específicas de WT1 (CTL) para la proteína WT1; un método para la detección o tratamiento de cáncer usando la secuencia nucleotídica o la secuencia de aminoácidos; y una placa, un conjunto de iniciadores, un equipo, un aparato y lo similar para usarse en la detección de cáncer, cada uno de los cuales comprende la secuencia nucleotídica o la secuencia de aminoácidos.
MX2009009589A 2007-03-05 2008-02-28 Gen receptor de celulas t especificas de antigeno cancerigeno, peptido codificado por el gen, y uso de los mismos. MX2009009589A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007054215 2007-03-05
PCT/JP2008/053469 WO2008108257A1 (ja) 2007-03-05 2008-02-28 癌抗原特異的ｔ細胞のレセプター遺伝子およびそれによりコードされるペプチドならびにそれらの使用

Publications (1)

Publication Number Publication Date
MX2009009589A true MX2009009589A (es) 2009-09-21

Family

ID=39738141

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2009009589A MX2009009589A (es) 2007-03-05 2008-02-28 Gen receptor de celulas t especificas de antigeno cancerigeno, peptido codificado por el gen, y uso de los mismos.
MX2014010820A MX343633B (es) 2007-03-05 2008-02-28 Gen receptor de celulas t especificas de antigeno cancerigeno, peptido codificado por el gen, y uso de los mismos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2014010820A MX343633B (es) 2007-03-05 2008-02-28 Gen receptor de celulas t especificas de antigeno cancerigeno, peptido codificado por el gen, y uso de los mismos.

Country Status (11)

Country Link
US (4) US10093977B2 (es)
EP (4) EP2857508A3 (es)
JP (3) JP5808079B2 (es)
KR (3) KR101773690B1 (es)
CN (2) CN103374576A (es)
AU (1) AU2008222061B2 (es)
BR (1) BRPI0808341A2 (es)
CA (1) CA2679045A1 (es)
MX (2) MX2009009589A (es)
TW (2) TWI615469B (es)
WO (1) WO2008108257A1 (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1842603B (zh) 2003-06-27 2013-09-11 株式会社国际癌症免疫研究所 选择适于wt1疫苗患者的方法
CN100513563C (zh) 2003-11-05 2009-07-15 株式会社国际癌症免疫研究所 Wt1衍生的hla-dr-结合抗原肽
CA2677075C (en) 2007-02-27 2018-07-10 International Institute Of Cancer Immunology, Inc. Method for activation of helper t cell and composition for use in the method
EA018456B1 (ru) * 2007-07-27 2013-08-30 Имматикс Байотекнолоджиз Гмбх Новые иммуногенные эпитопы для иммунотерапии
GB0721686D0 (en) * 2007-11-05 2007-12-12 Medinnova As Polypeptides
KR20140009168A (ko) 2010-10-05 2014-01-22 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 헬퍼 ｔ 세포의 활성화 방법
US9803246B2 (en) * 2011-06-28 2017-10-31 International Institute Of Cancer Immunology, Inc. Receptor gene for peptide cancer antigen-specific T cell
US9539299B2 (en) 2011-10-27 2017-01-10 International Institute Of Cancer Immunology, Inc. Combination therapy with WT1 peptide vaccine and temozolomide
US10391126B2 (en) 2011-11-18 2019-08-27 Board Of Regents, The University Of Texas System CAR+ T cells genetically modified to eliminate expression of T-cell receptor and/or HLA
WO2013166343A2 (en) * 2012-05-04 2013-11-07 Nuclea Biotechnologies, Inc. Mrm-ms signature assay
ES2655031T3 (es) * 2012-07-02 2018-02-16 Sumitomo Dainippon Pharma Co., Ltd. Preparación transdérmica de péptido antigénico del cáncer
CN104797711B (zh) * 2012-09-12 2018-09-21 株式会社癌免疫研究所 抗原特异性辅助性t细胞受体基因
GB2508414A (en) * 2012-11-30 2014-06-04 Max Delbrueck Centrum Tumour specific T cell receptors (TCRs)
JP6530192B2 (ja) 2012-12-17 2019-06-12 大塚製薬株式会社 ヘルパーｔ細胞の活性化方法
JP6250288B2 (ja) * 2013-01-30 2017-12-20 株式会社医学生物学研究所 Ｔ細胞レセプターおよびその利用
CA2905588C (en) 2013-03-12 2018-11-06 Sumitomo Dainippon Pharma Co., Ltd. Liquid aqueous composition
CN106170297A (zh) * 2013-09-20 2016-11-30 纪念斯隆-凯特琳癌症中心 用于wt‑1‑阳性疾病的组合/辅助疗法
US11390921B2 (en) 2014-04-01 2022-07-19 Adaptive Biotechnologies Corporation Determining WT-1 specific T cells and WT-1 specific T cell receptors (TCRs)
ES2730325T3 (es) * 2014-04-24 2019-11-11 Univ Texas Aplicación de citoblastos pluripotentes inducidos para generar productos de terapia celular adoptiva
EP3067366A1 (en) * 2015-03-13 2016-09-14 Max-Delbrück-Centrum Für Molekulare Medizin Combined T cell receptor gene therapy of cancer against MHC I and MHC II-restricted epitopes of the tumor antigen NY-ESO-1
TWI726920B (zh) 2015-10-14 2021-05-11 耶魯大學 基因體規模的ｔ細胞活性陣列、其製造方法、其用於辨識免疫調節因子的方法及其用途
RU2019116312A (ru) 2016-11-14 2020-12-14 Фред Хатчинсон Кэнсер Рисерч Сентер Высокоаффинные tcr, специфичные к t-антигену полиомавируса клеток меркеля, и их применения
BR112019018863A8 (pt) * 2017-03-15 2023-05-02 Hutchinson Fred Cancer Res Tcrs de alta afinidade específicos para mage-a1 e usos dos mesmos
WO2018231958A1 (en) * 2017-06-13 2018-12-20 Adaptive Biotechnologies Corp. Determining wt-1 specific t cells and wt-1 specific t cell receptors (tcrs)
DE102017114737A1 (de) * 2017-06-30 2019-01-03 Immatics Biotechnologies Gmbh Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie
WO2019139972A1 (en) * 2018-01-09 2019-07-18 Board Of Regents, The University Of Texas System T cell receptors for immunotherapy
WO2019204338A1 (en) * 2018-04-16 2019-10-24 The Regents Of The University Of California Compositions and methods for cytotoxic cd4+t cells
US20210252057A1 (en) * 2018-05-16 2021-08-19 Fred Hutchinson Cancer Research Center Merkel cell polyomavirus t antigen-specific tcrs and uses thereof
CN112469733B (zh) * 2018-07-12 2022-04-19 深圳华大生命科学研究院 Mart-1(27-35)表位特异性t细胞受体
CN111116754A (zh) * 2018-10-30 2020-05-08 天津亨佳生物科技发展有限公司 一种针对egfr l858r基因突变的特异性tcr及其应用
GB201817821D0 (en) * 2018-10-31 2018-12-19 Ospedale San Raffaele Srl TCR and peptides
WO2020097530A2 (en) * 2018-11-09 2020-05-14 Fred Hutchinson Cancer Research Center Immunotherapy targeting mesothelin
EP3670530A1 (en) 2018-12-18 2020-06-24 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Cd22-specific t cell receptors and adoptive t cell therapy for treatment of b cell malignancies
US12528853B2 (en) 2019-06-21 2026-01-20 St. Jude Children's Research Hospital, Inc. T-cell receptor for treating fibrolamellar hepatocellular carcinoma
WO2021016109A1 (en) * 2019-07-19 2021-01-28 The Regents Of The University Of California T-cell receptors and methods of use thereof
WO2021060343A1 (ja) * 2019-09-24 2021-04-01 オンコセラピー・サイエンス株式会社 Ｕｒｌｃ１０由来ペプチドまたはｄｅｐｄｃ１由来ペプチドを認識するヒトｔ細胞が発現するｔ細胞受容体
WO2021217077A1 (en) * 2020-04-24 2021-10-28 The Board Of Trustees Of The Leland Stanford Junior University Novel t-cell specificities and uses thereof
JP7785696B2 (ja) * 2020-05-18 2025-12-15 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 操作されたｔ細胞受容体および使用の方法
CN111665359A (zh) * 2020-07-11 2020-09-15 成都益安博生物技术有限公司 一种肺癌的外周血tcr标志物及其检测试剂盒和应用
CN113092761A (zh) * 2021-03-15 2021-07-09 成都益安博生物技术有限公司 一种弥漫大b细胞淋巴瘤的外周血tcr标志物及其检测试剂盒和应用
CN113109564A (zh) * 2021-03-15 2021-07-13 成都益安博生物技术有限公司 一种急性髓细胞性白血病的外周血tcr标志物及其检测试剂盒和应用
IL308257A (en) 2021-05-05 2024-01-01 Immatics Biotechnologies Gmbh Antigen binding proteins that uniquely bind PRAME
WO2024092265A2 (en) * 2022-10-28 2024-05-02 Memorial Sloan-Kettering Cancer Center T cell receptors targeting ewsr1-wt1 fusion protein and uses thereof
AU2023397979A1 (en) * 2022-12-13 2025-07-03 Biontech Us Inc. T cell receptor constructs and uses thereof
WO2025096983A1 (en) * 2023-11-02 2025-05-08 Board Of Regents, The University Of Texas System Peptides and engineered t cell receptors targeting tpx2 antigen and methods of use

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4923799A (en) 1984-02-06 1990-05-08 The Ontario Cancer Institute T cell specific cDNA clone
US6582908B2 (en) * 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
CA2116526A1 (en) 1991-08-28 1993-03-18 William V. Williams T cell receptor-based therapy for rheumatoid arthritis
US5364787A (en) 1992-03-23 1994-11-15 Idaho Research Foundation Genes and enzymes involved in the microbial degradation of pentachlorophenol
US20060134641A1 (en) * 1992-05-22 2006-06-22 Franklin Richard L Treating viral infections with krill enzymes
US5494794A (en) * 1992-10-20 1996-02-27 Emory University Detection of mitochondrial DNA mutations associated with Alzheimer's disease and Parkinson's disease
US5672509A (en) * 1993-08-25 1997-09-30 Pfizer Inc. hPDE IV-C: a human phosphodiesterase IV isozyme
KR100262838B1 (ko) 1996-04-16 2003-03-15 기시모토 다다미쓰 고형암세포및조직이형성의검출방법,및골수이식및말초혈간세포이식용조직의검사방법
US5942422A (en) * 1996-11-14 1999-08-24 The Trustees Of Columbia University In The City Of New York Method for generating a directed, recombinant fusion nucleic acid
GB9710820D0 (en) 1997-05-27 1997-07-23 Univ Dundee Immunological method
US6013444A (en) * 1997-09-18 2000-01-11 Oligotrail, Llc DNA bracketing locus compatible standards for electrophoresis
WO1999027957A1 (en) * 1997-12-03 1999-06-10 The Immune Response Corporation Vaccination and methods against multiple sclerosis using specific tcr vbeta peptides
US6090593A (en) * 1998-05-13 2000-07-18 The United States Of America As Represented By The Secretary Of The Air Force Isolation of expressed genes in microorganisms
CA2327314A1 (en) 1998-05-19 1999-11-25 Avidex Limited Soluble t cell receptor
PT1103564E (pt) 1998-07-31 2009-03-13 Int Inst Cancer Immunology Inc Antigénios de cancro com base no produto do gene supressor de tumor wt1
KR100752065B1 (ko) 1998-09-30 2007-08-28 코릭사 코포레이션 Ｗｔ1 특이적 면역요법용 조성물 및 방법
US20030072767A1 (en) 1998-09-30 2003-04-17 Alexander Gaiger Compositions and methods for WT1 specific immunotherapy
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
GB9823897D0 (en) 1998-11-02 1998-12-30 Imp College Innovations Ltd Immunotherapeutic methods and molecules
HK1044965A1 (zh) 1999-02-23 2002-11-08 Baylor College Of Medicine T细胞受体Vβ-DβVβ序列和检测它的方法
EP1287357A2 (en) 2000-06-02 2003-03-05 Memorial Sloan-Kettering Cancer Center Artificial antigen presenting cells and methods of use thereof
EP1371664B1 (en) 2001-03-22 2008-01-09 International Institute of Cancer Immunology, Inc. Wti modified peptide
EP2014300B1 (en) 2001-06-29 2011-01-12 Chugai Seiyaku Kabushiki Kaisha Cancer vaccine comprising a cancer antigen based on the product of a tumor suppressor gene WT1 and a cationic liposome
EP1473564A4 (en) 2001-09-18 2008-12-10 Greenpeptide Co Ltd METHOD FOR DETECTING CELL IMMUNITY AND ITS APPLICATION TO MEDICAMENTS
EP1447091A4 (en) 2001-09-28 2008-02-13 Institute Of Can International NEW METHOD FOR INDUCTION OF ANTIGEN SPECIFIC T CELLS
WO2003028758A1 (en) 2001-09-28 2003-04-10 Haruo Sugiyama Novel method of inducing antigen-specific t cells
AU2003207528A1 (en) 2002-01-09 2003-07-30 Maxx Genetech Co. Ltd Method of detecting t-cell proliferation for diagnosis of diseases by gene array
US7214492B1 (en) * 2002-04-24 2007-05-08 The University Of North Carolina At Greensboro Nucleic acid arrays to monitor water and other ecosystems
EP1536009B1 (en) 2002-06-12 2010-04-28 International Institute of Cancer Immunology, Inc. Hla-a24-restricted cancer antigen peptide
US7342092B2 (en) 2002-09-12 2008-03-11 International Institute Of Cancer Immunology, Inc. Cancer antigen peptide formulations
WO2004063706A2 (en) * 2003-01-08 2004-07-29 Maxx Genetech Co., Ltd. Method of detecting over-expression of t-cell receptor genes by real-time pcr
CN1842603B (zh) * 2003-06-27 2013-09-11 株式会社国际癌症免疫研究所 选择适于wt1疫苗患者的方法
WO2005037868A2 (en) * 2003-10-16 2005-04-28 Case Western Reserve University Methods of treating nfat-related disorders
CN100513563C (zh) 2003-11-05 2009-07-15 株式会社国际癌症免疫研究所 Wt1衍生的hla-dr-结合抗原肽
US20070238099A1 (en) 2003-12-08 2007-10-11 Cohen Irun R Antigen Receptor Variable Region Typing
US7576183B2 (en) * 2003-12-24 2009-08-18 Los Alamos National Security, Llc Structure-based receptor MIMICS targeted against bacterial superantigen toxins
ATE462003T1 (de) 2004-03-31 2010-04-15 Int Inst Cancer Immunology Inc Aus wt1 stammende krebsantigenpeptide
GB0411771D0 (en) 2004-05-26 2004-06-30 Avidex Ltd Nucleoproteins displaying native T cell receptor libraries
US7674456B2 (en) * 2004-06-14 2010-03-09 Charles Wiseman Breast cancer cell lines and uses thereof
GB0427585D0 (en) 2004-12-16 2005-01-19 Avidex Ltd Assay
WO2008026927A2 (en) 2006-08-30 2008-03-06 Academisch Medisch Centrum Process for displaying t- and b-cell receptor repertoires
JP2009278927A (ja) 2008-05-23 2009-12-03 Tohoku Univ Ｔ細胞受容体を模倣する抗体断片及びその製造方法
US9803246B2 (en) 2011-06-28 2017-10-31 International Institute Of Cancer Immunology, Inc. Receptor gene for peptide cancer antigen-specific T cell

Also Published As

Publication number Publication date
CN101668853B (zh) 2013-07-31
KR101900639B1 (ko) 2018-09-19
EP3492590A3 (en) 2019-06-19
US20140315735A1 (en) 2014-10-23
KR20150103385A (ko) 2015-09-10
MX343633B (es) 2016-11-11
JP2016005466A (ja) 2016-01-14
US10093977B2 (en) 2018-10-09
EP3492590A2 (en) 2019-06-05
EP3173480A3 (en) 2017-08-16
EP2857508A3 (en) 2015-04-15
KR20170101317A (ko) 2017-09-05
EP2116596A1 (en) 2009-11-11
TWI615470B (zh) 2018-02-21
JP5832572B2 (ja) 2015-12-16
US10669584B2 (en) 2020-06-02
US20210017599A1 (en) 2021-01-21
EP2116596A4 (en) 2010-04-07
CN101668853A (zh) 2010-03-10
BRPI0808341A2 (pt) 2014-07-01
JPWO2008108257A1 (ja) 2010-06-17
US20100190163A1 (en) 2010-07-29
TW201514299A (zh) 2015-04-16
CA2679045A1 (en) 2008-09-12
TWI615469B (zh) 2018-02-21
CN103374576A (zh) 2013-10-30
JP5808079B2 (ja) 2015-11-10
KR101773690B1 (ko) 2017-08-31
WO2008108257A1 (ja) 2008-09-12
EP2857508A2 (en) 2015-04-08
JP2014176382A (ja) 2014-09-25
KR101669279B1 (ko) 2016-10-26
AU2008222061B2 (en) 2014-03-20
EP3173480A2 (en) 2017-05-31
KR20090127273A (ko) 2009-12-10
JP6268129B2 (ja) 2018-01-24
AU2008222061A1 (en) 2008-09-12
US20140315758A1 (en) 2014-10-23
TW200844225A (en) 2008-11-16

Similar Documents

Publication Publication Date Title
MX2009009589A (es) Gen receptor de celulas t especificas de antigeno cancerigeno, peptido codificado por el gen, y uso de los mismos.
EP3447140A3 (en) Receptor gene for peptide cancer antigen-specific t cell
CY1124632T1 (el) Προϊοντα συζευξης αναλογων cc-1065 και διλειτουργικοι συνδετες
NZ602119A (en) Peptide vaccines for cancers expressing tumor-associated antigens
MX2020005765A (es) Receptores de celulas t restringidos a antigeno leucocitario humano (hla) clase i contra sarcoma de rata (ras) mutado.
CL2018002763A1 (es) Moléculas de unión a bcma y métodos de uso de las mismas.
MX395287B (es) Nuevos receptores de linfocitos t e inmunoterapia basada en el uso de los mismos.
EA202090757A1 (ru) T-КЛЕТОЧНЫЕ РЕЦЕПТОРЫ, РАСПОЗНАЮЩИЕ МУТАНТНЫЙ p53
SA519410362B1 (ar) مستقبل للخلايا التائية (tcr) وببتيدات
PH12022551470A1 (en) Materials and methods for in vivo biological targeting
FI2884999T4 (fi) Menetelmä ja koostumuksia soluimmunoterapiaa varten
CY1119696T1 (el) Cc-1065 αναλογα και τα συζευγματα αυτων
EA201891670A1 (ru) Пептиды, комбинации пептидов и медикаменты на клеточной основе для применения в иммунотерапии рака мочевого пузыря и других видов рака
FI3294333T4 (fi) Klaudiini-18.2-spesifiset immunoreseptorit ja t-soluepitoopit
EP3276000A3 (en) Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
MX354450B (es) Anticuerpos anti proteína accesoria del receptor de interleucina-1 y su uso para tratamiento en humanos.
EP4234576A3 (en) Methods of isolating neoantigen-specific t cell receptor sequences
WO2017120428A3 (en) Compositions and libraries comprising recombinant t-cell receptors and methods of using recombinant t-cell receptors
CY1115186T1 (el) Παραγωγα cis-τετραϋδρο-σπειρο(κυκλοεξανο-1,1'-πυριδο[3,4-b]ινδολ)-4-αμινης
WO2007065957A3 (en) Methods for generating antigen-specific effector t cells
EP2668296A2 (en) Colon cancer gene expression signatures and methods of use
WO2009042570A3 (en) Modified t cell receptors and related materials and methods
IL292864A (en) New peptides and a combination of peptides and supports for use in immunotherapy in certain types of cancer
Ye et al. Endogenous retroviral proteins provide an immunodominant but not requisite antigen in a murine immunotherapy tumor model
EA201270607A1 (ru) Аденовирус обезьян и способы его использования

Legal Events

Date Code Title Description
FG Grant or registration